A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan

European Heart Journal

Volumn 36, Issue 47, 2015, Pages 3332-3342

  Kimura, Takeshi ^a   Kozuma, Ken ^b   Tanabe, Kengo ^c   Nakamura, Sunao ^d   Yamane, Masahisa ^e   Muramatsu, Toshiya ^f   Saito, Shigeru ^g   Yajima, Junji ^h   Hagiwara, Nobuhisa ⁱ   Mitsudo, Kazuaki ^j   Popma, Jeffrey J ^k   Serruys, Patrick W ^l,m   Onuma, Yoshinobu ^l   Ying, Shihwa ⁿ   Cao, Sherry ⁿ   Staehr, Peter ⁿ   Cheong, Wai Fung ⁿ   Kusano, Hajime ⁿ   Stone, Gregg W ^o  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY HOSPITAL   (Japan)

^c MITSUI MEMORIAL HOSPITAL   (Japan)

^d NEW TOKYO HOSPITAL   (Japan)

^e Saitama Sekishinkai Hospital   (Japan)

^f SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^g SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^h THE CARDIOVASCULAR INSTITUTE   (Japan)

ⁱ TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^j KURASHIKI CENTRAL HOSPITAL   (Japan)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁿ ABBOTT VASCULAR   (United States)

^o NewYork Presbyterian Hospital   (United States)

more..

Author keywords

Bioresorbable scaffold; Coronary stent; Restenosis; Thrombosis

Indexed keywords

CHROMIUM; COBALT; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT;

AGED; ARTICLE; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICE SAFETY; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAL STENT; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ELUTING STENT; GRAFT OCCLUSION, VASCULAR; HEART MUSCLE REVASCULARIZATION; MYOCARDIAL INFARCTION; OPERATION DURATION; PROCEDURES; PROSTHESIS DESIGN; TISSUE SCAFFOLD; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; OPERATIVE TIME; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; SINGLE-BLIND METHOD; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84946834512     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv435     Document Type: Article

References (20)

1. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L,WebsterMW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 2008;371:899-907.
2. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the Absorb everolimus eluting bioresorbable vascular scaffold: A multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014;9:1271-1284.
3. Simsek C, Karanasos A, Magro M, Garcia-Garcia HM, Onuma Y, Regar E, Boersma E, Serruys PW, van Geuns RJ. Long-Term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. EuroIntervention 2014; E-pub ahead of print.
4. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, MitudoK; j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: Five-year outcome of the j-Cypher Registry. Circulation 2012;125:584-591.
5. Serruys PW, Chevalier B, Dudek D, Cequier A, CarriéD, Iniguez A, Dominici M, van der Schaaf RJ, Haude M,Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015;385:43-54.
6. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S. Comparison of everolimus-And biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015;65:791-801.
7. Cutlip DE,Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
8. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990;9:1447-1454.
9. Cochran WG. Some methods for strengthening the common x2 test. Biometrics 1954;10:417-451.
10. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, DAscenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, DeWaha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-Analysis. Lancet 2012;379:1393-1402.
11. Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA; ABSORB Cohort A and B Investigators. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011;78:3-12.
12. Gomez-Lara J, Radu M, Brugaletta S, Farooq V, Diletti R, Onuma Y, Windecker S, Thuesen L, McClean D, Koolen J,Whitbourn R, Dudek D, Smits PC, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv 2011;4:992-1001.
13. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate endpoints in drug-eluting stent trials: A systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008;51:23-32.
14. Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, Umeda H, Kawai K, Okada H, Kimura K, Simonton CA, Kozuma K; RESET Investigators. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial (RESET). Circulation 2012;126:1225-1236.
15. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015;10:1144-1153.
16. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P, Serruys PW, SabatéM. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: The BVS-EXAMINATION Study (bioresorbable vascular scaffold-A clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). J Am Coll Cardiol Intv 2015;8:189-197.
17. Tamburino C, Latib A, van Geuns RJ, Sabate M, Mehilli J, Gori T, Achenbach S, Alvarez MP, Nef H, Lesiak M, Di Mario C, Colombo A, Naber CK, Caramanno G, Capranzano P, Brugaletta S, Geraci S, Araszkiewicz A, Mattesini A, Pyxaras SA, Rzeszutko L, Depukat R, Diletti R, Boone E, Capodanno D, Dudek D. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective. EuroIntervention 2015;11:45-52.
18. Ormiston JA, Webber B, Ubod B, Darremont O, Webster MW. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention 2015;11:60-67.
19. Wiebe J, Bauer T, Dorr O, Mollmann H, Ham CW, Nef HM. Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 mm showing evidence of self-correction. EuroIntervention 2015; E-pub ahead of print.
20. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol 2013;62:1563-1570.